![]() Inhaled liposomal amphotericin B 12.5 mg twice weekly is an alternative for Trial utilized inhaled liposomal amphotericin B reported a nearly 60% relative The most common adverse events were cough, bad taste, and nausea.ĭiscontinuation rates ranged from 0-45%. Both formulations were without reported systemic or severe adverseĮffects. Relative risk reductions for invasive aspergillosis were routinelyĤ0-60%. Three inhaled liposomalĪmphotericin B trials demonstrated similar reductions with 2 finding statistical Incidence, 1 reaching statistical significance. Three inhaledĪmphotericin B deoxycholate trials found a reduced invasive aspergillosis ![]() Six trials, 2 randomizedĬontrolled and 4 with historical controls, were identified. Malignancy treatment or stem cell transplant. This review summarizes the literature on inhaled amphotericin B for invasiveĪspergillosis prophylaxis in patients with neutropenia secondary to hematologic
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |